UT Health Science Center-San Antonio: Gene-Mutation Pathway Discovery Paves Way for Targeted Blood Cancers Therapies
October 23, 2024
October 23, 2024
SAN ANTONIO, Texas, Oct. 23 (TNSres) -- The University of Texas Health Science Center at San Antonio issued the following news release:
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function.
A study published Oct. 2 in Nature is the first to explain . . .
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function.
A study published Oct. 2 in Nature is the first to explain . . .